Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 22.42% is 303% above its 5-year average of -11.06%, near the high end of its 5-year range (-209.87%–27.51%).
13.57% above its 12-month average of 19.74%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 17.89%.
EBITDA MARGIN
22.42%
EBITDA MARGIN AVG TTM
19.74%
EBITDA MARGIN AVG 3Y
15.26%
EBITDA MARGIN AVG 5Y
-11.06%
EBITDA MARGIN AVG 10Y
-80.79%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+13.57%
CURRENT VS 3Y AVG
+46.89%
CURRENT VS 5Y AVG
+302.69%
CURRENT VS 10Y AVG
+127.75%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
TransMedics Group, Inc.
Market Cap
$2.99B
EBITDA Margin
22.42%
TTM Avg
19.74%
3Y Avg
15.26%
5Y Avg
-11.06%
Market Cap
$1.91B
EBITDA Margin
16.41%
TTM Avg
1.22%
3Y Avg
-1.65%
5Y Avg
4.31%
Market Cap
$1.14B
EBITDA Margin
3.96%
TTM Avg
-13.21%
3Y Avg
-146.19%
5Y Avg
-104.68%
Market Cap
$5.10B
EBITDA Margin
21.06%
TTM Avg
20.50%
3Y Avg
18.63%
5Y Avg
16.67%
Market Cap
$5.59B
EBITDA Margin
-395.82%
TTM Avg
-536.17%
3Y Avg
-471.62%
5Y Avg
-471.62%
Market Cap
$376.61M
EBITDA Margin
-48.80%
TTM Avg
-44.09%
3Y Avg
-45.35%
5Y Avg
-45.35%
Market Cap
$45.05M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TransMedics Group, Inc. (TMDX) | $2.99B | 22.42% | 19.74% | 15.26% | -11.06% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.91B | 16.41% | 1.22% | -1.65% | 4.31% |
| Teladoc Health, Inc. (TDOC)vs › | $1.14B | 3.96% | -13.21% | -146.19% | -104.68% |
| Doximity, Inc. (DOCS)vs › | $4.88B | 35.56% | 38.69% | 36.58% | 34.55% |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.10B | 21.06% | 20.50% | 18.63% | 16.67% |
| NRC Health (NRC)vs › | $463.35M | 21.99% | 25.40% | 28.98% | 31.97% |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.59B | -395.82% | -536.17% | -471.62% | -471.62% |
| Shoulder Innovations, Inc. (SI)vs › | $376.61M | -48.80% | -44.09% | -45.35% | -45.35% |
| PDS Biotechnology Corporation (PDSB)vs › | $45.05M | N/A | N/A | N/A | N/A |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.24B | 6.82% | 6.08% | -0.44% | -8.67% |
Gross Margin
58.7%
EBITDA Margin
22.4%
Operating Margin
12.2%
Net Margin
22.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 17.89% |
| 2026-03-31 | 14.47% |
| 2025-12-31 | 17.88% |
| 2025-09-30 | 20.96% |
| 2025-06-30 | 27.51% |
| 2025-03-31 | 23.39% |
| 2024-12-31 | 11.78% |
| 2024-09-30 | 8.37% |
| 2024-06-30 | 14.97% |
| 2024-03-31 | 17.37% |
| 2023-12-31 | 7.65% |
| 2023-09-30 | -39.80% |
| 2023-06-30 | 0.93% |
| 2023-03-31 | -1.93% |
| 2022-12-31 | -17.51% |
| 2022-09-30 | -18.12% |
| 2022-06-30 | -43.61% |
| 2022-03-31 | -55.81% |
| 2021-12-31 | -112.35% |
| 2021-09-30 | -209.87% |
| 2021-06-30 | -115.25% |
| 2021-03-31 | -85.95% |
| 2020-12-31 | -71.67% |
| 2020-09-30 | -59.34% |
| 2020-06-30 | -220.79% |
| 2020-03-31 | -101.54% |
| 2019-12-31 | -137.66% |
| 2019-09-28 | -95.91% |
| 2019-06-29 | -130.89% |
| 2019-03-30 | -122.26% |
| 2018-12-31 | -173.31% |
| 2018-09-30 | -92.25% |
| 2018-06-30 | -171.01% |
| 2018-03-31 | -183.21% |
| 2017-12-30 | -205.94% |
| 2017-09-30 | -243.92% |
| 2017-07-01 | -249.51% |
| 2017-04-01 | -293.78% |
